A native Australian millet may carry the genetic fingerprints of thousands of years of Aboriginal harvesting, storage, and plant management. Seen from the air, Channel Country resembles a vibrant and vast tapestry, with a network of waterways crisscrossing the land. Spread across more than 280,000 square kilometers in outback Australia, it is one of the [...]New research has revealed the complex biological history preserved in DNA traces on the Shroud of Turin. Fibers taken from the Shroud of Turin nearly five decades ago still contain a complex record of biological material accumulated over centuries. In research published in Scientific Reports, scientists applied advanced genomic sequencing (rigorous PCR-free next-generation metagenomic sequencing) [...]When the history of our ancestry is written, the fact that we've interbred with some of our closest relatives, the Neanderthals and Denisovans, will have a central role. And it will be tempting to write it as a very tidy story: Once we got genomes from these other groups, it was possible to identify the sequences in our genomes that we shared with them.
But in reality, as scientists started poking large enough collections of data, there were regular hints of some strange ancestry in our genomes. It was hard to pin down, though, at least in part because the 2 percent on average of Neanderthal DNA found in many populations does not guarantee that any two individuals will have the same 2 percent. So having the genomes of those two groups made sense of some things researchers had already been seeing.
But knowing what we do about Neanderthal and Denisovan DNA is now allowing researchers to answer a somewhat different question: Is there anything else? Using recently developed analytical techniques, they find evidence of a third lineage that we apparently interbred with before any modern humans left Africa. Again, there were hints of this earlier, but so far, there's been no genome from a modern human relative to help us understand the details—the source of this DNA remains a "ghost lineage."
© BSIP
When the history of our ancestry is written, the fact that we've interbred with some of our closest relatives, the Neanderthals and Denisovans, will have a central role. And it will be tempting to write it as a very tidy story: Once we got genomes from these other groups, it was possible to identify the sequences in our genomes that we shared with them.
But in reality, as scientists started poking large enough collections of data, there were regular hints of some strange ancestry in our genomes. It was hard to pin down, though, at least in part because the 2 percent on average of Neanderthal DNA found in many populations does not guarantee that any two individuals will have the same 2 percent. So having the genomes of those two groups made sense of some things researchers had already been seeing.
But knowing what we do about Neanderthal and Denisovan DNA is now allowing researchers to answer a somewhat different question: Is there anything else? Using recently developed analytical techniques, they find evidence of a third lineage that we apparently interbred with before any modern humans left Africa. Again, there were hints of this earlier, but so far, there has been no genome from a modern human relative to help us understand the details—the source of this DNA remains a "ghost lineage."
© BSIP
Chromosome instability and aneuploidy have long posed a conundrum in cancer biology, profoundly shaping tumor genomes yet remaining challenging to decode functionally. In a groundbreaking study published in Nature, Al-Zahrani et al. unveil a novel approach, CRISPR-KOALA, that systematically links large-scale chromosomal alterations to specific cancer-driving genes in basal-like breast cancer (BLBC).
BLBC, a highly aggressive subtype characterized by extensive copy-number alterations (CNAs), often harbors arm-level chromosomal imbalances whose contribution to tumorigenesis remains elusive. The researchers developed CRISPR-KOALA to conduct high-throughput bidirectional genetic screens directly in immunocompetent mouse models, overcoming previous barriers related to the complexity and scale of genes affected by aneuploidy.
By focusing on the ten most frequent human chromosome-arm alterations seen in BLBC, the team screened over 3,700 mouse orthologues of genes located on these arms. The screen identified 90 putative cancer driver genes—a majority of which had not been previously linked to cancer—revealing a diverse functional landscape shaping tumor biology. Among the implicated pathways were key signaling networks such as MAPK, HIPPO, and WNT, highlighting the heterogeneity intrinsic to BLBC progression.
Strikingly, manipulating these driver genes in Trp53-mutant mouse models was sufficient to bypass the need for whole-arm CNAs, suggesting that tumors exploit specific genes within broad chromosomal alterations to fuel oncogenesis. This finding challenges the traditional view that arm-level aneuploidies function merely as genomic chaos, instead presenting them as evolutionary selections for particular drivers.
One gene, PLGRKT, localized on chromosome 9p, emerged as a potent oncogene. The team showed that PLGRKT promotes tumor growth by enhancing mitochondrial robustness and boosting reactive oxygen species detoxification. This mechanistic insight connects chromosomal instability not only to genetic selection but also to metabolic adaptations that support cancer cell survival under stress.
Overall, this study delivers a transformative platform and a compendium of cancer drivers that illuminate how aneuploidy sculpts tumor heterogeneity. By delineating driver genes nested within widespread CNAs, it provides an invaluable resource for targeting breast cancer’s genetic complexity with greater precision.
The implications extend beyond breast cancer, offering a blueprint for dissecting arm-level aneuploidy in diverse malignancies. As cancer therapies increasingly focus on genetic vulnerabilities, CRISPR-KOALA represents a leap toward untangling the intricate link between chromosome-level alterations and oncogenic processes.
This work underscores the power of integrating genomic data with functional genetics in vivo, setting the stage for novel drug targets and therapeutic strategies aimed at the underexplored realm of aneuploidy-driven tumorigenesis.
Subject of Research: Chromosome instability and cancer driver genes in basal-like breast cancer
Article Title: Aneuploidy selects for the acquisition of driver genes in breast cancer
Article References:
Al-Zahrani, K.N., Langille, E.R., Nurtanto, J. et al. Aneuploidy selects for the acquisition of driver genes in breast cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10752-9
Image Credits: AI Generated
In an era marked by extraordinary advances in genomic science, pediatric medicine stands on the brink of a transformative revolution. Recent research, as highlighted in the 2026 John Howland Award Lecture by B.D. Gelb, reveals both the breathtaking pace of progress in pediatric genomic medicine and the imperative for measured, responsible integration. This evolving field is redefining the management and understanding of childhood diseases through the power of genomic technologies, yet it also confronts significant challenges that necessitate careful consideration.
At the core of pediatric genomic medicine is the ability to decode the human genome with unprecedented speed and resolution. Next-generation sequencing technologies have dramatically accelerated the identification of genetic variants associated with pediatric conditions, facilitating earlier diagnoses and more targeted therapies. This acceleration not only shortens diagnostic odysseys that often span years but also opens a window into personalized interventions that enhance efficacy and safety in young patients.
However, the speed of these advances demands caution. As Gelb emphasizes, the clinical application of genomic findings must be tempered by rigorous validation and ethical oversight. The rush to implement novel genomic tests and treatments without comprehensive understanding risks unintended consequences—ranging from misinterpretation of data to exacerbating health inequities. The pediatric population, uniquely vulnerable due to developmental considerations, requires a thoughtful approach that balances innovation with prudence.
One remarkable aspect of pediatric genomic medicine is its ability to elucidate rare genetic disorders that were previously enigmatic. Genomic sequencing has illuminated the molecular basis of numerous syndromes, enabling not only precise diagnosis but also shedding light on underlying biological pathways. This knowledge accelerates drug discovery and paves the way for novel therapeutic strategies tailored to the genetic makeup of each child, transitioning from a one-size-fits-all paradigm to precision medicine.
Data integration emerges as a crucial enabling factor in this field. Beyond raw sequencing data, combining clinical phenotypes, family history, and environmental factors enhances diagnostic accuracy. Advanced bioinformatics tools and artificial intelligence algorithms play integral roles in interpreting complex genomic datasets, filtering noise from clinically relevant signals. These computational advancements elevate pediatric genomic medicine from a purely descriptive science to a predictive and proactive discipline.
Yet, the ethical dimensions of pediatric genomics loom large. Issues surrounding informed consent, privacy, and data sharing become particularly complex when dealing with minors. Parents and guardians must navigate decisions that can affect the child’s present and future health, often mediated by uncertainties inherent to genomic interpretations. Responsible stewardship of genomic information necessitates frameworks that safeguard patient autonomy while promoting equitable access to advances.
The potential for genomic screening in newborns represents both an opportunity and a quandary. Early detection of genetic abnormalities could revolutionize preventive care and improve long-term outcomes. Nonetheless, the broader implications of widespread genomic screening require careful examination, including considerations of psychological impact, clinical utility, and cost-effectiveness. Balancing these factors will define the responsible trajectory of pediatric genomic screening programs.
An essential component of progress is the education and training of healthcare providers. Clinicians must be equipped with not only the technical understanding of genomic technologies but also the skills to counsel families effectively. Multidisciplinary teams integrating geneticists, bioinformaticians, ethicists, and pediatricians form the backbone of successful genomic medicine services, ensuring holistic patient care that accounts for biological and psychosocial dimensions.
The expanding landscape of pediatric genomic medicine also intersects with burgeoning fields such as gene editing and regenerative therapies. CRISPR-Cas9 and other tools offer the tantalizing prospect of correcting deleterious mutations at their source. Nonetheless, these approaches are nascent and fraught with scientific and ethical complexities, highlighting the necessity for robust preclinical studies and stringent regulatory oversight before clinical adoption.
International collaboration represents a powerful avenue for accelerating pediatric genomic research and equitable benefit. Shared databases, standardized protocols, and cross-border consortia facilitate the aggregation of genetic data from diverse populations—an essential factor in elucidating variant pathogenicity and expanding therapeutic horizons. Global efforts can help overcome the limitations of fragmented data and enhance the generalizability of genomic discoveries.
Importantly, the pediatric genomic medicine community recognizes the risk of exacerbating healthcare disparities. Technological advances tend to concentrate in well-resourced centers, potentially leaving underserved populations behind. Addressing these disparities requires concerted policy initiatives, public engagement, and infrastructure development to ensure that genomic medicine is accessible to all children, regardless of socioeconomic or geographic status.
Looking ahead, the integration of real-world data and longitudinal studies will be critical in refining the understanding of genomic variants’ penetrance and expressivity in pediatric populations. Such comprehensive datasets will inform dynamic risk models and adaptive therapeutic approaches, further personalizing pediatric care and optimizing outcomes across diverse clinical contexts.
In sum, the landscape of pediatric genomic medicine is one of breathtaking promise intertwined with considerable complexity. The rapid progression in genomic technologies propels the field into uncharted territory, demanding a measured pace that safeguards patient welfare while nurturing innovation. The insights from Gelb’s 2026 John Howland Award Lecture resonate as a clarion call to balance enthusiasm with responsibility, ensuring that the promise of genomics translates into tangible, equitable benefits for children worldwide.
As pediatric genomic medicine continues to evolve, the collaborative engagement of scientists, clinicians, ethicists, policymakers, and patient communities will be paramount. This multidisciplinary synergy will chart the course for harnessing genomic insights with precision and compassion, transforming pediatric healthcare in profound and enduring ways. The future, while bright, must be navigated with vigilance, wisdom, and inclusivity to realize the full potential of genomic medicine for the youngest and most vulnerable members of society.
Subject of Research: Pediatric Genomic Medicine and its clinical and ethical advancement.
Article Title: Pediatric Genomic Medicine—rapid progress, but not too fast: American Pediatric Society’s 2026 John Howland Award Lecture.
Article References:
Gelb, B.D. Pediatric Genomic Medicine—rapid progress, but not too fast: American Pediatric Society’s 2026 John Howland Award Lecture. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05233-8
Image Credits: AI Generated
In the ever-evolving field of genomics, a significant leap has been achieved with the introduction of the PGS Browser, a novel public platform designed to transform the way researchers, clinicians, and individuals interact with polygenic scores. Polygenic scores (PGS) are quantitative measures that capture the cumulative effect of numerous genetic variants across the genome, predicting an individual’s predisposition to complex traits and diseases. This new platform promises not just accessibility but also interpretative power, enabling a personalized approach to genomic data that could reshape personalized medicine and risk assessment paradigms worldwide.
At the heart of this transformative tool lies a sophisticated integration of vast genomic datasets, advanced computational algorithms, and user-friendly interfaces. The PGS Browser aggregates polygenic scores derived from an array of large-scale genome-wide association studies (GWAS), providing an unprecedented resource where users can explore the genetic architecture of diverse traits. One of the platform’s most compelling features is its capacity to personalize polygenic risk predictions by incorporating individual genetic data with contextual healthcare analytics, bridging the longstanding gap between raw genetic information and actionable clinical insights.
Traditionally, polygenic scores have been calculated using fixed sets of genetic variants, often constrained by limited population samples or specific ancestral backgrounds. This poses significant challenges regarding the portability and generalizability of these scores across diverse populations. The PGS Browser addresses this limitation head-on by incorporating multi-ancestry datasets and advanced statistical models that recalibrate polygenic scores for diverse genetic ancestries. This opens new horizons in achieving equity in genomic medicine, ensuring individuals from underrepresented populations have access to precise, contextually relevant risk evaluations.
The technical backbone of the PGS Browser involves complex methodologies that include linkage disequilibrium (LD) adjustment, penalized regression frameworks, and machine learning techniques, all optimized for high-throughput and scalable analysis. These computational advances optimize the balance between predictive accuracy and overfitting, a persistent challenge in polygenic score modeling. By dynamically adjusting for confounding genomic features and population stratification, the platform produces risk scores that are both statistically robust and biologically interpretable.
One of the critical innovations within the platform is its interpretability module, designed to unpack the black-box nature of polygenic predictions. Users are not only presented with their personalized polygenic scores but also receive detailed visualizations and annotations explaining the contribution of key genetic loci, biological pathways involved, and potential gene-environment interactions. This level of detail empowers clinicians to make informed decisions and patients to understand the genetic basis of their risks, paving the way for targeted preventative strategies and lifestyle modifications.
From a healthcare perspective, the implications of the PGS Browser extend far beyond academic research. The platform is a strategic tool for genetic counseling, allowing healthcare providers to identify individuals at elevated risk for complex diseases such as cardiovascular disease, diabetes, and certain cancers before clinical symptoms manifest. Early identification through polygenic risk enables preemptive interventions, personalized monitoring, and tailored therapeutic approaches, underscoring a shift from reactive to proactive medicine.
Moreover, the PGS Browser operates with a commitment to transparency and reproducibility, addressing critical concerns in genetic epidemiology. All computational workflows are openly accessible, enabling peer verification and fostering collaborative improvement. The platform also integrates with existing biobank data through standardized protocols, facilitating validation studies and meta-analyses that enhance the reliability of polygenic scores across global cohorts.
A particularly noteworthy aspect of the platform is its potential role in pharmacogenomics. By correlating polygenic scores with drug response phenotypes, the browser could assist in identifying individuals who might benefit from specific medications or require dosage adjustments. This integration with personalized medicine elevates the clinical utility of polygenic scores from risk stratification to therapeutic optimization, highlighting the multi-dimensional impact of genomic data in patient care.
The PGS Browser also bridges the gap between research and public engagement. Designed with intuitive navigation and educational resources, it invites an increasingly genomically literate public to explore their genetic predispositions within a responsible and secure framework. This democratization of genetic information fosters greater awareness and empowerment while maintaining stringent privacy standards, an essential consideration in the era of big data.
In operational terms, the platform boasts scalability features capable of handling millions of individuals’ data concurrently, a necessity given the rapid expansion of genomic databases worldwide. The utilization of cloud-based infrastructures, coupled with containerized computational environments, ensures flexible deployment across various institutional settings while preserving data security and compliance with regulatory frameworks such as GDPR.
From a scientific perspective, the availability of such a public platform catalyzes the discovery of novel gene-trait associations by allowing researchers to perform systematic, large-scale analyses that correlate polygenic scores with phenotypic data. This accelerates the identification of biological mechanisms underlying complex traits, informing subsequent functional studies and therapeutic development pipelines.
Ethical considerations permeate the development and deployment of the PGS Browser. The platform incorporates informed consent modules, guidelines on interpretation limitations, and warnings against deterministic views of genetic risk. By fostering responsible use and interpretation, the platform promotes ethical standards within a field where genetic data can easily be misunderstood or misapplied.
Furthermore, the PGS Browser represents a leap forward in standardizing polygenic score methodologies. Historically, disparate scoring algorithms and variable reporting conventions have hindered comparability across studies. This unified platform offers a harmonized framework that promotes methodological consistency, enabling the scientific community to consolidate findings and build upon a shared foundation.
The cross-disciplinary collaboration manifested in the creation of the PGS Browser highlights the convergence of genetics, bioinformatics, data science, and clinical medicine. This integrative approach is crucial to addressing the complexities of polygenic risk and translating genomic insights into tangible health benefits, marking a pivotal moment in the genomics era.
Looking forward, the PGS Browser sets the stage for continuous evolution. Planned enhancements include integration with longitudinal health records, expansion of trait coverage particularly in psychiatric and neurological domains, and real-time updating as new GWAS data emerge. Such adaptability ensures the platform remains at the forefront of personalized genomics research and application.
In conclusion, the PGS Browser embodies a landmark achievement in the democratization and personalization of polygenic score analysis. By merging rigorous computational techniques with accessible design and ethical mindfulness, it empowers a broad spectrum of users to harness the predictive power of genomic data. This innovation holds transformative potential for healthcare, research, and public understanding, catalyzing a new era in precision medicine where genetic insights are personalized, interpretable, and actionable like never before.
Subject of Research: Development and deployment of a public platform for personalized polygenic score analysis and interpretation.
Article Title: PGS Browser: A Public Platform for Personalized Polygenic Score Analysis and Interpretation.
Article References:
Kolosov, N., Reeve, M.P., Briotta Parolo, P.D. et al. PGS Browser: a public platform for personalized polygenic score analysis and interpretation. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74461-7
Image Credits: AI Generated
Last week, we looked at a new study of the origin of complex cells, one that showed that our ancestors' genomes were pieced together from bits and pieces of multiple species. It put a spotlight on a phenomenon called horizontal gene transfer, in which a gene from one species is incorporated into the genome of a distantly related species. The frequency of horizontal gene transfer means that, in addition to the neatly branching trees that relate species by common descent, there are small threads connecting distant branches of the tree of life.
It's easy to see why horizontal gene transfer would be common among microbes. They often live in complex communities that are likely awash in the DNA of dead and damaged cells. Plus, bacteria and archaea lack a membrane between their DNA and the rest of the cell, making it easier for environmental DNA to find its way to the genome.
However, a new study this week shows that horizontal gene transfers are remarkably common even in multicellular animals. And it does so by examining the genomes of multiple cockroach species, which have had bits of bacterial DNA for millions of years.
© Nugroho Ridho
Last week, we looked at a new study of the origin of complex cells, one that showed that our ancestors' genomes were pieced together from bits and pieces of multiple species. It put a spotlight on a phenomenon called horizontal gene transfer, in which a gene from one species is incorporated into the genome of a distantly related species. The frequency of horizontal gene transfer means that, in addition to the neatly branching trees that relate species by common descent, there are small threads connecting distant branches of the tree of life.
It's easy to see why horizontal gene transfer would be common among microbes. They often live in complex communities that are likely awash in the DNA of dead and damaged cells. Plus, bacteria and archaea lack a membrane between their DNA and the rest of the cell, making it easier for environmental DNA to find its way to the genome.
However, a new study this week shows that horizontal gene transfers are remarkably common even in multicellular animals. And it does so by examining the genomes of multiple cockroach species, which have had bits of bacterial DNA for millions of years.
© Nugroho Ridho
As our world is rapidly reshaped by climate change, glaciers have retreated and revealed new swaths of bare land. Throughout the coming decades to centuries, this rocky ground will become dappled with lichens and scrub, eventually giving rise to newborn forests in a process known as ecological succession.
Ecologists have mapped out the stages of ecological succession for plant communities, observing which species are the first to colonize land and how these pioneer species promote secondary growth. Yet before any plants sink their roots into the soil, it is populated by thriving communities of single-celled microbes that prepare it for further habitation. Scientists study how these microbial communities arise to understand how healthy ecosystems develop.
Newly exposed land is nutrient-poor and subject to large temperature fluctuations, so the first species to settle there must overcome these challenges. Pioneer plant species are often habitat generalists, meaning they can thrive under a variety of environmental conditions. However, all plants convert water and sunlight into carbon and energy. Microbes can use many different energy sources, and often contain genes for multiple metabolisms in their genomes. Therefore, researchers wondered whether pioneer microbes could also be defined by their metabolic flexibility.
A team of scientists based at Monash University in Australia tested this hypothesis by studying land left in the wake of 2 retreating glaciers: one on an island off the coast of Antarctica and one in the Swiss Alps. The researchers sampled soils along a path from the tip of the glacier outward, which had been exposed to the air for different amounts of time. By comparing the microbial communities within these soils, the researchers could track the different stages of ecological succession after glacial retreat.
The researchers extracted DNA from the soils and analyzed it using 2 sequencing methods. First, they sequenced a gene called 16S rRNA, which is like a microbial fingerprint for the different species present. They used this method to understand the diversity of these communities and track their species overlap, helping them to identify habitat generalists that thrived under different soil conditions.
To understand the metabolic flexibility of these microbes, the researchers used a second method, known as metagenomics, which sequences all of the DNA in a sample rather than just a single gene. They used these data to reconstruct the entire genomes of microbes present in the soils, providing information on what kinds of metabolic activities they were capable of. The team also measured chemicals like ammonium and sulfide in the soils, as well as atmospheric gases like methane and carbon monoxide, to assess how the microbes used these compounds for growth.
The researchers found microbes inhabiting even the youngest soils, demonstrating the speed at which life takes hold in new environments. The abundance of microbes increased by approximately 8-fold in older soils, alongside a similar rise in species diversity, indicating that complex communities persisted over time. They also found the metabolic capabilities of microbes inhabiting Antarctic and Swiss glacial soils to be remarkably similar, suggesting common selective pressures drove the establishment of these new ecosystems.
They were surprised to discover that the most abundant microbes in younger soils were habitat specialists that were rare in older soils. These pioneer microbes, while still metabolically flexible, had adapted to utilize meager energy sources like atmospheric trace gases, including hydrogen, methane, and carbon monoxide. Many of these microbes could also derive energy from chemicals that dissolved out of rocks, like inorganic sulfur compounds. The researchers proposed that pioneer microbes could quickly take advantage of newly opened ecological niches, like soils exposed during a glacier’s retreat, because of their efficiency at using scant resources.
They found that habitat generalists, on the other hand, tended to dominate older soils. This result suggested that the habitat specialists were eventually outcompeted by the slow and steady growth of the habitat generalists in a real-life turtle-and-hare race.
The team concluded that using multiple growth strategies helps microbes adapt to new environments. However, they acknowledged that ecological succession could occur differently in other landscapes, such as in the aftermath of volcanic eruptions, meteorite impacts, or forest fires. They suggested that future researchers work to uncover how microbial communities lay the groundwork across these diverse ecosystems.
The post When glaciers retreat, microbes take over appeared first on Sciworthy.
We tend to view ourselves and the complex cells that build us as a distinct branch of the tree of life from the compact, seemingly featureless cells of bacteria and archaea. But we've found that our genome is actually a hybrid, a mish-mash of genes from bacteria and archaea, along with some that have evolved in our own lineage.
Scientists gradually settled on a simple explanation for this: the first complex cells were the product of a fusion between archaeal cells and bacteria, with the bacteria ultimately evolving into the mitochondria, a chemical-power-generating structure that still retains a bit of its own genome. Over time, many of the other bacterial genes were transferred to the nucleus of what was becoming what we now call a eukaryote, intermingling with the archaeal genes there.
But a new study has taken a careful look at some of the genes shared by all eukaryotes and comes to the conclusion that the reality is a little more complicated and that there were several waves of gene transfers from bacteria. The big picture of a merger between bacteria and archaea is still right, but it was only part of a picture where gene transfers among species were commonplace.
© MARK GARLICK/SCIENCE PHOTO LIBRARY
Login